Summary Report of Consolidated Financial Results
For the Three Months Period ended June 30, 2015

August 11, 2015
stCompany name: NIPRO CORPORATION
TSE-1 section
Code No.8086
URL: http://www.nipro.co.jp/
Representative: Yoshihiko Sano, President and Representative Director
Contact person: Kimihito Minoura, Director and General Manager of Corporate Planning Headquarters
TEL: (06)6372-2331
Filing date of quarterly reporting: August 14, 2015
Payment date of cash dividends: Supplemental material on quarterly reporting: No
Presentation on quarterly results: No(Note: Amounts are truncated to one million yen)
1. Consolidated Results for the Three Months ended June 30, 2015 (From April 1, 2015 to June 30, 2015)(1) Consolidated Results of Operations(Note: % of change from the same period a year ago)
Net Sales
Operating Income
Ordinary Income
Net Income
Millions of yen% Millions of yen% Millions of yen% Millions of yen%
3 months ended June 30, 2015
88,097
16.8
5,476
95.5
5,852
172.6
3,904 211.9
3 months ended June 30, 2014
75,424
7.6
2,801
10.5
2,146
(50.3)
1,252 (48.7)
Note: Comprehensive income 3 months ended June 30, 2015: 2,885 million yen (142.1%) 3 months ended June 30, 2014: 1,191 million yen((95.1)%)3 months ended June 30, 2015
3 months ended June 30, 2014

Earnings per share
Yen
23.03
8.31

(2) Consolidated Financial Position
Total Assets
Millions of yen
3 months ended June 30, 2015
680,139
Year ended March 31, 2015
695,306
Note: Equity

2.

Diluted Earnings per share
Yen
7.40

Net Assets
Millions of yen
177,651
178,8103 months ended June 30, 2015: 167,244 million yen

Equity Ratio
%
24.6
24.1

Year ended March 31, 2015: 167,659 million yen

Dividends

Year ended March 31, 2015
Year ending March 31, 2016
Year ending March 31, 2016
(Forecast)First-quarter
Yen-

Annual Dividends per Year
Year-end Dividends
Second-quarter
Third-quarter
Yen
Yen
Yen
18.00
14.50
16.00

-

18.50

Annual Dividends

Yen
32.50
34.50

Note: Revisions to the forecast of cash dividends in the current quarter: No
3. Forecast of Consolidated Financial Results for the Year ending March 31, 2016 (From April 1, 2015 to March 31, 2016)(Note: The % displays in the line of six months ending Sept. 30, 2015 show increase/decrease ratio against the six months
ended Sept. 30, 2014. The % displays in the line of year ending March 31, 2016 show increase/decrease ratio against theyear ended March 31, 2015
OperatingEarnings
Net Sales
Ordinary Income
Net Income
Incomeper Share
Millions of yen%
Millions of yen%
Millions of yen%
Millions of yen%
Yen
6 months ending Sept. 30, 2015
174,000 12.6
12,700
60.0
9,700
12.5
3,950 (27.8)
23.30
Year ending March 31, 2016
362,000 11.4
27,50065.9
22,50014.4
13,7009.980.80
Note: Revisions to the forecast of consolidated financial results in the current quarter: No

*Notes(1) Change in Significant Subsidiaries during the Current Period(Change in specified subsidiaries caused a change in the scope of consolidation): No
Additional: 0Removal: 0(2) Adoption of Accounting Treatments Simplified or Unique for Preparation: No(3) Change in Accounting Policies and Accounting Estimate and Restatement[1] Changes in accounting policies by a newly issued accounting pronouncement: Yes[2] Changes other than [1]: No[3] Change in accounting estimate: No[4] Restatement: No
Note: More information can be found in P.4 “2. Summary (Other) Information, (3) Changes in Accounting Policies andAccounting Estimate and Restatement” in the attachment.
(4) Issued Shares (Common stock)[1] Number of issued shares at end of the period (including treasury stock):
3 months ended June 30, 2015: 171,459,479 sharesYear ended March 31, 2015: 171,459,479 shares[2] Number of treasury stock at end of the period:
3 months ended June 30, 2015: 1,862,131 sharesYear ended March 31, 2015:
1,899,861 shares[3] Average number of shares during the period:
3 months ended June 30, 2015: 169,572,552 shares
3 months ended June 30, 2014: 150,741,720 shares
Note: Number of the treasury stocks as of June 30, 2015 included 915,100 shares, and as of March 31, 2015 included
953,100 shares owned by Trust and Custody Service Bank, Ltd (Trust Account E).
*Information regarding the quarterly review procedure
This quarterly summary report is exempt from quarterly review procedure based on the Financial Instruments
and Exchanges Act. It is under the review procedure process at the time of disclosure of this report.
*Disclaimer regarding projection information including appropriate use of forecasted financial result, and otherspecial notes
The projection figures shown above are based on information that was available at the time of preparation and may
contain certain uncertainties. Actual performance and other factors may differ from these projections due tochanges in circumstances and other developments. More information concerning these forecasts can be found in P.4“1. Qualitative Information for the Three-Month Period Ended June 30, 2015, (3) Commentary on Forward-Looking
Statements Including Forecast of Consolidated Financial Results” in the attachment.

Table of Contents
1.

2.

3.

Qualitative Information for the Three-Months Period ended June 30, 20152(1) Commentary on Business Results

2(2) Analysis Concerning Financial Position

4(3) Commentary on Forward-Looking Statements Including Forecast of Consolidated Financial Results

4

Summary (Other) Information

4(1) Changes in Significant Consolidated Subsidiaries

4(2) Accounting Treatments Simplified or Unique for Preparation

4(3) Changes in Accounting Policies and Accounting Estimate and Restatement

4

Consolidated Financial Statements

6(1) Quarterly Consolidated Balance Sheets

6(2) Quarterly Consolidated Statements of Income andQuarterly Consolidated Statements of Comprehensive Income

8(3) Notes Regarding Consolidated Financial Statement

9(Notes regarding going concern)

9(Notes regarding significant changes in the amount of shareholders’ equity)

9(Segment Information)

9-1-

1. Qualitative Information for the Three-Month Period Ended June 30, 2015
(1) Commentary on Business Results
During the three months of the fiscal year under review, the global economy generally remained on a recovery trend
following the previous year’s trend despite the uncertainty about the economic outlook such as concerns about theEuropean debt crisis and the economic slowdown in China. The Japanese economy also remained on a recovery trend
and saw improvements in corporate earnings and the employment environment as the yen generally remained at low
levels and stock prices generally remained at high levels.
Under such circumstances, the Nipro Group has worked to improve operating results through its continued efforts to
expand sales and reduce costs.
As a result, consolidated sales for the three-month period ended June 30, 2015 increased by 16.8% from the same
period of the previous year to 88,097 million yen. As for the profit, consolidated operating income increased by 95.5% fromthe same period of the previous year to 5,476 million yen. Consolidated ordinary income increased by 172.6% from thesame period of the previous year to 5,852 million yen due to the foreign exchange gain from the depreciation of the yen.
Consolidated net income attributable to owners of the parent increased by 211.9% from the same period of the previous
year to 3,904 million yen.
The overview of the results for the current quarter period under review by business segment is as follows.

(i)

Medical-Related Business
Domestic sales of Medical-Related Business were on a recovery trend as the market that was unstable following thechanges due to the increase in the consumption tax rate, the revision of medical treatment fees and reimbursement
prices, etc., in the previous year was relatively calm. Under such circumstances, the Medical Sales Division acquired the
medical business of Unitika Ltd. in April 2015 and started selling its products under the Nipro brand. As a result, we cannow expect a market expansion in related fields based on the synergy effect with the existing products and are able toprovide a wider variety of services through the consolidation of distribution channels and aggregation of productinformation. As for existing products, sales of cardiac surgery (CVS) products were below expectations as the number ofcases using implantable ventricular assisting devices dropped slightly while injection-transfusion products,
enteral-alimentation products, testing products, dialysis products, and cardiovascular products performed solidly. On theother hand, for the Pharmaceutical Sales Division, the sales were steady due to the expansion of the market with thepromotion policy of generic drugs and the launch of addenda listing items in June though the competitive environment ofdomestic market became fiercer by the appearance of manufactures of original drugs running sideline business. In
addition, large markets of new big listing items have being continuously entered by over 30 competitors and initial salesof AG (authorized generic) allows to market occupation, that made the market price competition more intensified to
impact significantly to sales and profit. However, we have strengthened the sales promotion to dispensing pharmacies,
diagnosis procedure combination (DPC) hospitals and prescribers. Also we tried to increase the share of drugs for oral
and external use and worked harder for information offering activities of injectable drugs based on the collaboration withpharmaceutical wholesaler and Medical Sales Division.
Meanwhile, overseas sales as well as profits increased significantly from the same period of the previous year as we
strengthened the sales of dialysis products and hospital products, partially supported by the improved export profitability
under the weaker yen versus dollar environment in the foreign exchange market. In particular, in the North American
market in which we established a strategic location in the previous year, sales were brisk as we aggressively pushedforward with alliances with major customers. We strengthened the overseas sales organization and stepped up our direct
sales activities with the aim of quickly responding further to front-line needs and boosting overseas sales. In particular,
we established an independent sales division in India to expand sales and are opening sales offices in major cities of thecountry one by one.
New overseas manufacturing facilities (in India, Indonesia, Bangladesh and Hefei in China) further improved theirproduction system and realized stable production expansion under established quality system to promote their sales-2-

widely in their countries and surrounding areas. Especially production of dialyzers in India and Hefei plants has increasedsmoothly to contribute the sales increase and syringe from Indonesia plants has supported the sales growth as well.
As a result, net sales of this business increased by 18.9% from the same period of the previous year to 64,528 million
yen.

(ii)

Pharmaceutical-Related BusinessIn the Pharmaceutical-Related Business, we have broadened our contracted manufacturing operation to encompass
contracts to develop products from the formulation design of drugs for oral and external use and to develop products using
our expertise developing and supplying vials, syringes, bags, and other packaging containers. We also endeavored to
expand the contracted business by offering a diverse range of detailed yet wide-ranging contract services, such assupport for lifecycle management where we believe we can enhance the value-added features and realize distinct service
differentiation. In addition, efforts to upgrade and expand our contracted manufacturing capabilities for the dedicatedbiopharmaceuticals line and the oral drugs and injectable solutions lines at the high potency active pharmaceuticalingredients manufacturing plant contributed to strong sales of contracted manufacturing.
Sales of pharmaceutical containers as well as devices related to pharmaceutical preparation and administration steadily
increased due to offering containers and systems suitable to each pharmaceutical product. Such efforts were made tomeet various needs in the medical front, including small-volume bags, materials for pre-filled syringes (plastic and glass),
etc., on top of rubber stoppers for pharmaceutical and vaccine use and containers for kit products. We developed thecontainers and systems by ourselves or through joint development with pharmaceutical manufactures based on our
processing technologies for plastics, rubbers, and metals. In addition, under the government’s policy to curb medical
expenses, we have worked together with domestic and foreign pharmaceutical manufactures in enhancing
comprehensive lifecycle management of pharmaceutical products, taking into consideration the development of
combination products (our original collaboration between pharmaceutical products and medical devices), self-injection
systems, and dosage form/administrating path modification in the future.
As a result, net sales of this business increased 9.8% from the same period of the previous year to 15,505 million yen.

(iii) Glass-Related BusinessIn the Glass-Related Business, adding to our conventional products, we have made effort of sales activities to acquire
global customer needs and new demands while we have promoted the development of new technologies and new
products to support injectable formulation with high stability.
For the pharmaceutical packaging in domestic glass department, we increased the sales mainly in vials and prefilled
syringe. As for “Biwako Factory,” a state-of-the-art plant for pharmaceutical packaging, with the purpose of further
improving our quality assurance system for good manufacturing practice (GMP), the factory aims to establish the
production and sales system of high quality glass for medical purpose and promotes their activities to meet the needsfrom global customers. Among other glass-related products, overseas demands of glass for thermos bottles decreased
but whole sales of this department remained solidly.
Regarding overseas glass department, on the other hand, sales and profit of vial and ampoule have increased stably in
India and China under the changing of market that requires high-quality medical containers in developing countries. In
Europe and the United States, the performance is getting improved based on the investment we made in the past and thehigh-tech prefilled syringe has marked fine sales.
As a result, net sales of this business increased 15.2% from the same period of the previous year to 8,055 million yen.

(iv) Other BusinessAmong other business, sales from the real-estate rental business were 8 million yen (down by 81.2% from the same
period of the previous year).

-3-(2) Analysis Concerning Financial Position
Analysis Concerning the Conditions of Assets, Liabilities and Net Assets
Total assets decreased by 15,167 million yen from the end of the previous year to 680,139 million yen. Current assets
decreased by 13,571 million yen primarily due to a decrease of 16,220 million yen in cash and deposits, and noncurrent
assets decreased by 1,596 million yen primarily due to a decrease of 1,879 million yen in deferred tax assets.
Total liabilities decreased by 14,008 million yen from the end of the previous year to 502,488 million yen. Current
liabilities increased by 8,608 million yen primarily due to an increase of 14,578 million yen in short-term loans payable,
and noncurrent liabilities decreased by 22,617 million yen primarily due to a decrease of 22,428 million yen in long-termloans payable.
Total net assets decreased by 1,159 million yen from the end of the previous year to 177,651 million yen. Shareholders’equity increased by 656 million yen and accumulated other comprehensive income decreased by 1,071 million yen.
(3) Commentary on Forward-Looking Statements Including Forecast of Consolidated Financial Results
The Company expects that the global economy will continue to stay on a moderate recovery trend despite the increasing
uncertainty about the future outlook and the Japanese economy will also remain on a recovery trend while it will be affectedby the global trend.
Even under such circumstances, the Nipro Group will work to improve profits through its continued efforts to expand
sales and reduce production costs.
At this moment, we have not made any revision to the forecast of consolidated financial results for the year ending
March 31, 2016, which was announced on May 13, 2015.
2. Summary (Other) Information(1) Changes in Significant Consolidated Subsidiaries
N/A(2) Accounting Treatments Simplified or Unique for Preparation
N/A(3) Changes in Accounting Policies and Accounting Estimate and Restatement(Change in Accounting Policies)
Application of the Accounting Standard for Business Combinations and related accounting standards
The Company has applied the “Accounting Standard for Business Combinations” (ASBJ Statement No. 21, September
13, 2013; hereinafter the “Accounting Standard for Business Combinations”), “Accounting Standard for Consolidated
Financial Statements” (ASBJ Statement No. 22, September 13, 2013; hereinafter the “Accounting Standard forConsolidated Financial Statements”), and “Accounting Standard for Business Divestitures” (ASBJ Statement No. 7,
September 13, 2013; hereinafter the “Accounting Standard for Business Divestitures”), etc., effective from the first quarter
under review. As a result, the method of recording the amount of difference caused by changes in the Company’sownership interests in subsidiaries in the case of subsidiaries under ongoing control of the Company was changed to one
in which it is recorded as capital surplus, and the method of recording acquisition-related costs was changed to one inwhich they are recognized as expenses for the fiscal year in which they are incurred.
Furthermore, for business combinations carried out on or after the beginning of the first quarter under review, theaccounting method was changed to one in which the reviewed acquisition cost allocation resulting from the finalization of
the tentative accounting treatment is reflected in the quarterly consolidated financial statements for the quarterly period inwhich the business combination occurs.
In addition, a change in the presentation of quarterly net income, etc. and a change in the presentation of the minority
interests to non-controlling interests were adopted. In order to reflect these changes in presentation, the quarterly-4-consolidated financial statements for the first quarter of the previous fiscal year and the consolidated financial statements
for the previous fiscal year were reclassified. The application of the Accounting Standard for Business Combinations andrelated accounting standards is subject to the transitional treatment provided for in Paragraph 58-2 (4) of the AccountingStandard for Business Combinations, Paragraph 44-5 (4) of the Accounting Standard for Consolidated Financial
Statements, and Paragraph 57-4 (4) of the Accounting Standard for Business Divestitures. Accordingly, these standards
have been applied prospectively from the beginning of the first quarter under review.
As a result, capital surplus decreased 635 million yen and retained earnings decreased 167 million in the current
quarterly period under review. There was no impact of this change on the consolidated statements of income.

-5-

3. Consolidated Financial Statements(1) [ Quarterly Consolidated Balance Sheets](Millions of yen)
As ofMarch 31, 2015
AssetsCurrent Assets
Cash and deposits
Notes and accounts receivable-trade
Merchandise and finished goods
Work in process
Raw materials and supplies
Deferred tax assets
Other
Allowance for doubtful accounts
Total current assets
Noncurrent assets
Property, plant and equipment
Bulidings and structures
Accumulated depreciation and impairment loss
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation and impairment loss
Machinery equipment and vehicles, net
Land
Lease assets
Accumulated depreciation
Lease assets, net
Construction in progress
Other
Accumulated depreciation and impairment loss
Other, net
Total property, plant and equipment
Intangible assets
Goodwill
Lease assets
Other
Total intangible assets
Investments and other assets
Investment securities
Net defined benefit asset
Deferred tax assets
Other
Allowance for doubtful accounts
Total investments and other assets
Total noncurrent assets
Total assets

-6-

As of
June 30, 2015

112,871
114,477
67,412
12,14922,913
6,963
16,341(2,783)350,346

96,651
113,81466,268
11,74225,336
7,550
17,697(2,287)
336,774

174,138(81,157)
92,980212,911(150,454)
62,45722,027
3,058(1,957)
1,100
31,242
42,619(32,232)
10,387220,195

174,872(82,361)
92,511
212,855(152,214)
60,641
21,746
2,918(1,899)1,019
32,01843,939(32,722)
11,216219,154

26,364
1,625
16,37944,36926,0591,635
15,85743,55264,076140
7,899
11,901(3,622)80,395344,960
695,306

65,577437
6,019
12,190(3,568)80,656343,364
680,139

(Millions of yen)
As ofMarch 31, 2015
Liabilities
Current liabilities
Notes and accounts payable-trade
Short-term loans payable
Commercial papers
Current portion of bonds
Lease obligations
Accounts payable-otherAccrued directors' bounuses
Income taxes payable
Provision for bounuses
Provision for directors' bounuses
Notes payable - facilities
Other
Total current liabilities
Noncurrent liabilities
Bonds payable
Long-term loans payable
Lease obligations
Deferred tax liabilities
Net defined benefit liability
Provision for directors' retirement benefits
Provision for loss on litigation
Other
Total noncurrent liabilities
Total liabilities
Net assets
Shareholders' equity
Capital stock
Capital surplus
Retained earnings
Treasury stock
Total shareholders' equity
Accumulated other comprehensive income
Valuation difference on available-for-sale securities
Deferred gains or losses on hedges
Foreign currency translation adjustment
Remeasurements of defined benefit plans
Total accumulated other comprehensive income
Non-controlling interests
Total net assets
Total liabilities and net assets

-7-

As of
June 30, 2015

51,750136,359
10,00027,840828
11,679
436
3,934
3,621
123
2,641
29,184278,401

55,494150,938
10,00028,740
1,093
9,811
－
2,998
3,020
133
5,023
19,756
287,009

20,592
205,621
3,127
2,162
3,841
524
11
2,214
238,095
516,496

19,400183,192
4,001
2,046
4,047
529
10
2,249
215,478
502,488

84,397635
58,885(1,686)142,231

84,397－60,143(1,652)
142,888(2,311)39
27,870(170)
25,427
11,150178,810695,306(556)
1
25,050(139)
24,356
10,406
177,651
680,139

(2) [Quarterly Consolidated Statements of Income and Quarterly Consolidated Statement of Comprehensive Income]Quarterly Consolidated Statements of Income(Amount: million yen)
FY2014 first three months(From April 1, 2014
to June 30, 2014)
Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating income
Non-operating income
Interest income
Dividends income
Foreign exchange gain
Reversal of allowance for doubtful accounts
Other
Total non-operating income
Non-operating expenses
Interest expenses
Foreign exchange losses
Equity in losses of affiliates
Other
Total non-operating expenses
Ordinary income
Extraordinary income
Gain on sales of noncurrent assets
Compensation income
Gain on sales of investment securities
Other
Total extraordinary income
Extraordinary loss
Loss on retirement of noncurrent assets
Structural integration expenses
Loss on sales of investment securities
Provision of allowance for doubtful accounts
Other
Total extraordinary losses
Income before income taxes
Income taxes-current
Income taxes-deferred
Total income taxes
Net income
Net income attributable to non-controlling interests
Net income attributable to owners of parent

FY2015 first three months(From April 1, 2015
to June 30, 2015)

75,42453,09722,327
19,526
2,801

88,09760,04728,05022,573
5,476

179
827
－
6
276
1,289

178
154
860
528
261
1,984

1,030
522
40
351
1,944
2,146

1,075
－
47
486
1,608
5,852

24
28
2,535
25
2,613

253
－
－
5
259

19
2
1,233
－
46
1,301
3,458
545
1,606
2,152
1,306
54
1,252

27
－
－
10
12
50
6,061
2,026
44
2,071
3,990
85
3,904

Qarterly Consolidated Statements of Comprehensive Income(Amount: million yen)
FY2014 first three months(From April 1, 2014
to June 30, 2014)
Net income
Other comprehensive income
Valuation difference on available-for-sale securities
Deferred gains or losses on hedges
Foreign currency translation adjustment
Remeasurements of defined benefit plans
Share of other comprehensive income of entities
accounted for using equity method
Total other comprehensive income
Comprehensive income
Comprehensive income attributable to owners of the parent
Comprehensive income attributable to non-controlling interests-8-

FY2015 first three months(From April 1, 2015
to June 30, 2015)

1,306

3,990

2,428
(55)
(2,524)
36

1,755
(37)
(2,861)
31

－

7

(114)
1,191
1,443
(251)

(1,105)
2,885
2,833
51

(3) Notes Regarding Consolidated Financial Statement(Notes regarding going concern)
N/A(Notes regarding significant changes in the amount of shareholders’ equity)
N/A(Segment Information)
FY2014 (From April 1, 2014 to June 30, 2014)

Ⅰ
1.

Sales and Profit by Reportable Operating Segment(Millions of yen)Segment
MedicalRelated

PharmaceuticalRelated

GlassRelated

Total

Other
(Note.1)

Total

Consolidated
Statements ofIncome(Note.3)

Adjustment(Note.2)

Net sales(1)Sales to third parties

54,273

14,117

6,990

75,38143

75,424-75,424(2)Inter-segment sales
and transfers

396

2,030

181

2,608

8

2,617

(2,617)-

Total

54,67016,147

7,171

77,99052

78,042(2,617)75,424

Segment profit

4,165

2,978

(665)

6,478

50

6,528

(2,617)2,801(Notes)
1.
2.
3.
2.

“Other” is the business segment which is not included in the segment and consist of real estate income and sales
by headquarter.
Adjustment for the segment profit of (3,727) million yen includes elimination of inter-segment transaction of (927)
million yen and corporate cost of (2,799) million yen. Corporate cost consisted primarily of general andadministrative expenses and research and development cost which do not belong to the reporting segment.
Segment profit is adjusted to the operating income on the consolidated statements of income.

Information about Impairment Loss on Fixed Assets and Goodwill by Reportable Operating Segment
N/A

-9-

Ⅱ
1.

FY2014 (From April 1, 2015 to June 30, 2015)
Sales and Profit by Reportable Operating Segment(Millions of yen)Segment
MedicalRelated

PharmaceuticalRelated

GlassRelated

Total

Other
(Note.1)

Total

Consolidated
Statements ofIncome(Note.3)

Adjustment(Note.2)

Net sales(1)Sales to third parties

64,52815,505

8,055

88,0898

88,097-88,097(2)Inter-segment sales
and transfers

432

2,096

237

2,766

8

2,775

(2,775)-

Total

64,961

17,601

8,293

90,856

16

90,873(2,775)88,097

Segment profit

6,853

2,832

(466)

9,218

16

9,234

(3,758)5,476(Notes)1.
2.
3.

“Other” is the business segment which is not included in the segment and consist of real estate income and sales
by headquarter.
Adjustment for the segment profit of (3,758) million yen includes elimination of inter-segment transaction of (90)million yen and corporate cost of (3,667) million yen. Corporate cost consisted primarily of general andadministrative expenses and research and development cost which do not belong to the reporting segment.
Segment profit is adjusted to the operating income on the consolidated statements of income.

2. Changes in Reportable Segments
Effective from the second quarter ended September 30, 2014, Nipro Glass India PVT. LTD., Nipro Tube Glass PVT.
LTD., Nipro Glass Americas Corporation, Nipro Glass France S.A.S., Nipro Glass Belgium N.V., Nipro Pharma Glass AG,
Nipro Glass Germany AG, Nipro Sterile Glass Germany AG, Chengdu Pingyuan Nipro Pharmaceutical Packaging Co., Ltd.,
Jilin Nipro Jiaheng Pharmaceutical Packaging Co., Ltd. and Anyang Nipro Changda Pharmaceutical Packaging Co., Ltd.,OOO Ural Glass Plant and Puyang City Changda Glass Co., Ltd. were reclassified from Medical-Related Business to
Glass-Related Business with current review of organization system in Nipro group.
Segment information as of June 30,2014 was based on this reclassification.
3. Information on Impairment Loss on Fixed Assets and on Goodwill by Reportable Segment
N/A- 10 -